What Is a Cosmetic vs a Medicine? How UK Regulation Defines the Difference
Published by AmpleLab Research
If you have spent time reading hair loss product copy, you will have noticed a certain pattern in the language. Products "support the scalp environment," they "help maintain the appearance of thicker hair," they "are formulated for" particular conditions. They rarely say "treats hair loss" or "regrows hair" or "prevents baldness." This is not an accident, and it is not straightforwardly the result of weak products being cautiously worded. It is the result of a legal distinction that most buyers are not aware of: the difference between a cosmetic and a medicine in UK law, and the consequences that follow from which category a product falls into.
Understanding this distinction matters for two reasons. It explains why legitimate brands hedge their claims in ways that can look like weakness but are actually regulatory precision. And it helps identify when a brand is making claims that are either legally problematic or inconsistent with how their product is actually classified.
Under UK law (specifically the Cosmetic Products Enforcement Regulations 2013, implementing EU Regulation 1223/2009 as retained in UK law) a cosmetic product is defined as any substance or mixture intended to be placed in contact with the external parts of the human body, including the skin, hair, nails, lips, or external genitalia, or with the teeth and oral mucous membranes, with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition, or correcting body odours.
That definition is broader than most people assume. A cosmetic is not just a moisturiser or a lipstick. A serum applied to the scalp to maintain hair condition is a cosmetic. A shampoo is a cosmetic. A product formulated to support the appearance of hair density is a cosmetic. What makes it a cosmetic is a combination of how it is applied, what it is intended to do, and how it presents itself to consumers.
In Great Britain, cosmetic products must be notified on the Submit Cosmetic Product Notification (SCPN) system operated by the Office for Product Safety and Standards (OPSS) before being placed on the market. This notification includes the formula, the responsible person, and safety documentation. It does not involve clinical trial evidence of efficacy; cosmetics are not approved for efficacy, only regulated for safety.
A medicine is defined under the Human Medicines Regulations 2012 as a substance or combination of substances presented as having properties for treating or preventing disease in human beings, or any substance or combination of substances that may be used in or administered to human beings with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action. Medicines in the UK are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
To be sold as a medicine in the UK, a product must hold a marketing authorisation (previously called a product licence) granted by the MHRA or, for certain categories, be registered under a simplified scheme. Obtaining a marketing authorisation requires demonstrating quality, safety, and efficacy through clinical trial evidence to the MHRA's standards. The route to market for a medicine is substantially more demanding than for a cosmetic, and the claims a licensed medicine can make are directly tied to the indications covered by its marketing authorisation.
Minoxidil is the most relevant example in the hair loss context. Minoxidil 2% and 5% topical solutions and foams are licensed medicines in the UK for the treatment of androgenetic alopecia. They can legally say they treat hair loss because they have gone through the clinical trial and regulatory process that permits that claim. An unlicensed topical serum cannot make the same claim.
The classification of a product as a cosmetic or medicine is determined by two criteria, and either one is sufficient to push a product into the medicines category:
If a product is presented as having properties for treating or preventing a disease, through its name, labelling, information leaflet, or any other means, it is classified as a medicine. Presentation includes not just the label but advertising copy, social media, and any content associated with the product. A topical serum that says "treats androgenetic alopecia" or "prevents pattern baldness" is presenting itself as a medicine regardless of what its formula actually contains.
If a product contains an ingredient that exerts a pharmacological, immunological, or metabolic action, it may be classified as a medicine on the basis of its function, regardless of how it presents itself. This is where genuinely borderline products arise. A product containing a compound that is known to block an enzyme, suppress a hormonal signal, or modify cellular signalling in a way that constitutes pharmacological action enters a regulatory grey area, even if the product is otherwise labelled as a cosmetic.
Either criterion is sufficient
A product can be regulated as a medicine because of its claims even if its formula is cosmetic. And a product can be regulated as a medicine because of its formula even if its claims are cosmetic. The stricter classification applies. This is why the boundary is not always obvious from the label alone.
The EU Common Criteria for Cosmetic Claims, set out in EU Regulation 655/2013 and retained in UK law, establish that cosmetic claims must be honest, evidenced, and not imply medical effects. In practice, this creates a visible vocabulary difference between how licensed medicines and cosmetics describe what they do.
The language on the right side of that table is medicines language. Using it for an unlicensed cosmetic is not just a regulatory technicality; it is a false claim about what the product is legally permitted to say. Brands that make those claims for unlicensed products are either misinformed about the regulatory framework or disregarding it.
The intuitive reading of cautious claims language is that the brand lacks confidence in the product. This is sometimes true but often backwards. A brand that has thought carefully about what the evidence actually supports, and has mapped its claims language accordingly, is demonstrating exactly the kind of epistemic discipline that should be associated with products formulated on genuine research foundations.
The research on copper peptides, for instance, is in vitro and animal-model based for the most part. A brand that says "GHK-Cu treats hair loss" is making a claim that goes far beyond what the evidence shows. A brand that says "research suggests GHK-Cu may support the follicular microenvironment" is describing what the evidence actually supports. The second formulation is not less confident; it is more precise. It is also what a cosmetic can legally say, which is a separate but related point.
Conversely, a brand in the hair loss category that makes strong therapeutic claims ("clinically proven to regrow hair," "stops hair loss," "reverses balding") without holding a marketing authorisation for a medicine is either making an unlicensed medicine claim for a cosmetic, or has failed to properly classify their product. Neither is a reassuring signal about the rigour of their approach to formulation or evidence.
The hair loss category is one of the more complex areas to navigate because the population of available products includes both licensed medicines and cosmetics that operate in adjacent territory. Understanding which is which helps set expectations correctly.
Minoxidil topical products (2% and 5%) are licensed medicines in the UK. Finasteride 1mg is a licensed medicine. Dutasteride is a licensed medicine. These products went through clinical trials and obtained marketing authorisations from the MHRA. Their licensed indications define what they can say about treating hair loss, and those claims are supported by the clinical evidence submitted to obtain the licence.
Copper peptide serums, 2-deoxy-D-ribose serums, and compounds like PTD-DBM are cosmetics. They have not obtained marketing authorisations. They are not approved treatments for any condition. Their potential value is as supportive actives that operate on the follicular microenvironment alongside, not instead of, the interventions that carry licensed evidence. The article on five questions to ask before buying a hair loss product covers how to evaluate these distinctions when making purchasing decisions.
The practical question for someone building a protocol is not "is this a cosmetic or a medicine?" as an evaluation of quality. Both categories can contain well-formulated, evidence-grounded products and poorly formulated, overclaiming products. The question is whether the product's claims are consistent with its regulatory status, and whether its evidence base is accurately described. These are the signals that distinguish brands worth taking seriously from those that are not.
All AmpleLab products are cosmetics, notified on the UK SCPN system. None hold or claim marketing authorisations as medicines. This classification is reflected in the claims language used throughout: "supports," "helps maintain," "research suggests," "in that animal model," "for the scalp environment." This language is calibrated to what cosmetics can say and what the available evidence actually supports for each active, not adopted as a defensive measure against stronger claims.
AmpleLab products are positioned as adjuncts to, not replacements for, the interventions that carry licensed evidence. The framework for how different approaches sit relative to each other is covered in the hair loss protocol guide.
Cosmetic Products Enforcement Regulations 2013 (SI 2013/1478)
The primary UK legislation governing cosmetic product safety, notification, and labelling. Includes the legal definition of a cosmetic product.
Human Medicines Regulations 2012 (SI 2012/1916)
The primary UK legislation governing medicinal products for human use. Includes the legal definition of a medicine and the requirements for marketing authorisations.
Regulation (EC) No 1223/2009 on Cosmetic Products
The source EU cosmetics regulation, retained in UK law post-Brexit. Article 2 contains the definition of a cosmetic product.
OPSS Guidance: Cosmetic Products Technical Guidance
UK Government guidance on cosmetic product regulation in Great Britain, including notification requirements and borderline product classification.
Can a cosmetic serum treat hair loss?
Not in the regulatory sense of "treat." A cosmetic cannot make treatment claims for a disease. Whether a cosmetic can have a meaningful positive effect on the scalp environment is a separate question, one answered by the quality of its formulation and the evidence base for its actives. A cosmetic that supports the follicular microenvironment can be valuable as part of a protocol without being a treatment in the licensed medical sense.
Why does minoxidil have different rules from a copper peptide serum?
Because minoxidil topical products for hair loss hold marketing authorisations as medicines in the UK. They went through the clinical trial process and obtained regulatory approval from the MHRA to make treatment claims. This authorisation allows them to say "treats androgenetic alopecia" because the evidence supports that claim to the MHRA's standards. A copper peptide serum is a cosmetic and has not been through that process, both because the evidence base would not currently support it and because the regulatory route for cosmetics is different and does not involve efficacy approval.
If a product claims to "regrow hair," should I be suspicious?
It depends on whether the product is a licensed medicine or a cosmetic. If it is a licensed minoxidil product, that claim is permitted within its licensed indication. If it is an unlicensed cosmetic serum making regrowth claims, the brand is either making an impermissible claim for a cosmetic or has failed to properly classify their product. Either possibility is worth noting when evaluating that brand's reliability on other questions, including formulation quality and evidence accuracy.
What is SCPN registration?
The Submit Cosmetic Product Notification system, operated by the UK's Office for Product Safety and Standards (OPSS). Before placing a cosmetic product on the market in Great Britain, the responsible person must notify the product on this system, providing the formula, the name and address of the responsible person, and reference to a safety assessment. SCPN registration confirms that a cosmetic is known to regulators and that a responsible person has taken on compliance obligations. It does not constitute approval of efficacy claims.
Does cautious claims language mean a product doesn't work?
Not at all. Cautious claims language for a cosmetic means the brand has correctly understood what their product's regulatory status permits and what their evidence base actually supports. A brand saying "research in mouse models suggests this compound may support follicle activity" is being accurate about the state of the evidence. This is a different situation from a brand with human clinical trial data for a licensed medicine saying the same thing. The quality of the claim should be evaluated relative to the type of product; cosmetics operate within a different and more limited claims framework than licensed medicines, and accurate claims within that framework should not be read as an admission of inefficacy.
This article provides general educational information about UK cosmetics and medicines regulation and does not constitute legal advice. Regulatory classifications involve product-specific assessment. For queries about a specific product's regulatory status, consult a qualified regulatory affairs professional or contact the MHRA or OPSS directly.
AmpleLab.